 |
Journal articles
A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.
Antonio Scardino
1
Maurizio Alimandi
2, 3
Pierpaolo Correale
4
Steven G Smith
5
Roberto Bei
6
Hüseyin Firat
7
Maria Grazia Cusi
4
Olivier Faure
1
Stephanie Graf-Dubois
1
Giulia Cencioni
2
Jordan Marrocco
2
Salem Chouaib
1
François A Lemonnier
7
Andrew Michael Jackson
5
Kostas Kosmatopoulos
1
Antonio Scardino 1
Author
Maurizio Alimandi 2, 3
Author
Pierpaolo Correale 4
Author
Steven G Smith 5
Author
Stephanie Graf-Dubois 1
Author
Giulia Cencioni 2
Author
Jordan Marrocco 2
Author
Salem Chouaib 1
Author
1
U753 - Cytokines et Immunologie des Tumeurs Humaines (Gustave Roussy. 114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France)
- UP11 - Université Paris-Sud - Paris 11 (Bâtiment 300 - 91405 Orsay cedex - France)
- IGR - Institut Gustave Roussy : U753 (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U753 (101, rue de Tolbiac, 75013 Paris - France)
4
Divisione di Oncologia Medica (Siena - Italy)
- UNISI - Università degli Studi di Siena (Rettorato - Via Banchi di Sotto 55 - 53100 Siena - Italy)
- Facoltà di Medicina (France)
5
Academic Division of Oncology (City Hospital Nottingham - United Kingdom)
- UON - University of Nottingham, UK (University of Nottingham University Park Nottingham NG7 2RD - United Kingdom)
6
Dipartimento di Medicina Sperimentale e Scienze Biochimiche (Vergata - Italy)
- Università di tor (France)
7
Immunité Cellulaire Antivirale (25-28 rue du Docteur Roux, F-75724 Paris Cedex 15 - France)
- Institut Pasteur [Paris] (25-28, rue du docteur Roux, 75724 Paris cedex 15 - France)
Abstract : A cDNA vaccine (pVax1/pet-neu) was designed to encode 12 different Her-2/ErbB-2-derived, HLA-A*0201-restricted dominant and high-affinity heteroclitic cryptic epitopes. Vaccination with pVax1/pet-neu triggered multiple and ErbB-2-specific CTL responses in HLA-A*0201 transgenic HHD mice and in HLA-A*0201 healthy donors in vitro. Human and murine CTL specific for each one of the 12 ErbB-2 peptides recognized in vitro both human and murine tumor cells overexpressing endogenous ErbB-2. Furthermore, vaccination of HHD mice with pVax1/pet-neu significantly delayed the in vivo growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) more actively when compared with vaccination with the empty vector (pVax1) or vehicle alone. These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes.
Document type :
Journal articles
Domain :
Complete list of metadatas
https://hal-pasteur.archives-ouvertes.fr/pasteur-00167482
Contributor : François Lemonnier <>
Submitted on : Tuesday, August 21, 2007 - 9:41:47 AM
Last modification on : Wednesday, October 14, 2020 - 3:45:48 AM
Contributor : François Lemonnier <>
Submitted on : Tuesday, August 21, 2007 - 9:41:47 AM
Last modification on : Wednesday, October 14, 2020 - 3:45:48 AM
Links full text
Identifiers
- HAL Id : pasteur-00167482, version 1
- DOI : 10.1158/0008-5472.CAN-06-3998
- PUBMED : 17638916
Citation
Antonio Scardino, Maurizio Alimandi, Pierpaolo Correale, Steven G Smith, Roberto Bei, et al.. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.. Cancer Research, American Association for Cancer Research, 2007, 67 (14), pp.7028-36. ⟨10.1158/0008-5472.CAN-06-3998⟩. ⟨pasteur-00167482⟩
Metrics
Record views